As you all know all too well, the medication options for IBS are quite limited. Thus, it is always refreshing to hear that drug manufacturers are working to change this unfortunate state of affairs. Lexicon Pharmaceuticals has just announced some positive results of a Phase II clinical trial for a medication currently being called LX1031.
LX1031 is designed to treat "non-constipating" IBS. In this trial, patients were recruited who suffer from diarrhea-predominant IBS (IBS-D) or IBS alternating type (IBS-A). Results showed significant improvement in relief of IBS pain and discomfort, as well as stool consistency as compared to placebo. The medication was well-tolerated with no evidence of adverse side effects.
LX1031 is described as a "tryptophan hydroxylase (TPH) inhibitor". Luckily, the press release offers an explanation! TPH is involved with production of the neurotransmitter serotonin in the intestinal tract. LX1031 is thought to decrease the amount of serotonin in the digestive system thus providing symptom relief. (If this topic interests you, see: The Brain Gut Connection in IBS). One of the study measurements was to assess the amount of 5-HIAA in urine, which is a measure of the breakdown of serotonin. As was hoped, study results indicated a decrease in the amount of 5-HIAA in the urine of participants who received LX1031.
The fact that this medication is looking effective without nasty side effects is good news! What I am liking about this medication is that it works to alleviate pain, which many of you would describe as your worst IBS symptom. Because the medication did well in this study, the manufacturer will continue to test it for safety and effectiveness. I will keep you posted!
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome Lexicon Pharmaceuticals Press Release. November 12, 2009.
|| Twitter | Newsletter Signup | Forum ||